The advisory committee will review the latest scientific data, including information on circulating variants and global trends. Their recommendation will help determine which strains should be included in the next round of vaccines to offer the best protection.
This process mirrors the annual flu vaccine update and aims to prepare for a possible rise in cases during the colder months. Once the advisers make their recommendation, the FDA will guide vaccine manufacturers like Pfizer, Moderna, and Novavax to begin production of the new formula.
The updated vaccines are expected to be available by fall 2025. Health officials continue to encourage vaccination, especially for people who are older or have underlying health conditions, to reduce the risk of severe illness.
